PriceTargets.com logo

Vor Biopharma - VOR Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $50.56
  • Forecasted Upside: 265.02%
  • Number of Analysts: 13
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 6 Buy Ratings
  • 2 Strong Buy Ratings
$13.85 As of 05/1/2026 05:00 PM ET
▼ -0.48 (-3.35%)

This chart shows the closing price for VOR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vor Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VOR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VOR

Analyst Price Target is $50.56
▲ +265.02% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Vor Biopharma in the last 3 months. The average price target is $50.56, with a high forecast of $120.00 and a low forecast of $15.00. The average price target represents a 265.02% upside from the last price of $13.85.

This chart shows the closing price for VOR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 13 polled investment analysts is to moderate buy stock in Vor Biopharma. This rating has held steady since December 2025, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 2 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2026
  • 2 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
4/3/2026
  • 2 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
5/3/2026

Latest Recommendations

  • 2 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/30/2026Jefferies Financial GroupUpgradeStrong-Buy
4/15/2026HC WainwrightLower TargetBuy ➝ Buy$32.00 ➝ $31.00
3/31/2026WedbushBoost TargetNeutral ➝ Neutral$15.00
3/30/2026Jefferies Financial GroupInitiated CoverageBuy$50.00
3/29/2026Jefferies Financial GroupUpgradeStrong-Buy
3/19/2026Wells Fargo & CompanyInitiated CoverageOverweight$30.00
1/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/9/2026CitigroupInitiated CoverageBuy$50.00
12/19/2025JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$43.00 ➝ $40.00
12/17/2025TD CowenInitiated CoverageBuy
12/9/2025JPMorgan Chase & Co.Initiated CoverageOverweight$43.00
11/25/2025WedbushInitiated CoverageNeutral
11/14/2025HC WainwrightLower TargetBuy ➝ Buy$55.00 ➝ $32.00
11/11/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
10/29/2025HC WainwrightBoost TargetBuy ➝ Buy$52.00
10/15/2025Robert W. BairdUpgradeNeutral ➝ Outperform$20.00 ➝ $64.00
10/13/2025Zacks ResearchDowngradeHold ➝ Strong Sell
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/24/2025Stifel NicolausUpgradeHold ➝ Buy$55.00
9/10/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
8/14/2025HC WainwrightReiterated RatingBuy ➝ Buy$60.00
8/12/2025Zacks ResearchUpgradeStrong Sell
6/30/2025HC WainwrightUpgradeHold ➝ Strong-Buy$60.00
6/26/2025WedbushReiterated RatingNeutral ➝ Outperform
5/9/2025Citizens JmpDowngradeStrong-Buy ➝ Hold
5/9/2025Citizens JmpReiterated RatingMarket Outperform ➝ Market Perform$120.00 ➝ $120.00
5/9/2025HC WainwrightReiterated RatingBuy ➝ Neutral
5/8/2025JonesTradingDowngradeStrong-Buy ➝ Hold
5/8/2025Robert W. BairdDowngradeStrong-Buy ➝ Hold
5/8/2025WedbushReiterated RatingOutperform ➝ Neutral$140.00 ➝ $8.00
3/21/2025OppenheimerReiterated RatingOutperform ➝ Outperform$160.00 ➝ $160.00
3/21/2025HC WainwrightLower TargetBuy ➝ Buy$350.00 ➝ $260.00
3/21/2025Stifel NicolausLower TargetBuy ➝ Buy$240.00 ➝ $100.00
3/20/2025WedbushReiterated RatingOutperform$140.00
12/10/2024Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$240.00 ➝ $240.00
12/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$350.00 ➝ $350.00
12/9/2024WedbushReiterated RatingOutperform$220.00
11/8/2024WedbushReiterated RatingOutperform$220.00
11/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$350.00 ➝ $350.00
11/8/2024Robert W. BairdLower TargetOutperform ➝ Outperform$440.00 ➝ $280.00
9/6/2024Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$240.00 ➝ $240.00
9/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$350.00 ➝ $350.00
8/14/2024BarclaysLower TargetOverweight ➝ Overweight$200.00 ➝ $60.00
5/13/2024Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$240.00
5/13/2024OppenheimerReiterated RatingOutperform ➝ Outperform$300.00 ➝ $200.00
5/10/2024WedbushReiterated RatingOutperform ➝ Outperform$220.00
4/23/2024WedbushReiterated RatingOutperform ➝ Outperform$220.00
3/22/2024Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$240.00
3/21/2024Stifel NicolausLower TargetBuy ➝ Buy$300.00 ➝ $240.00
3/21/2024OppenheimerReiterated RatingOutperform ➝ Outperform$340.00 ➝ $300.00
3/21/2024WedbushReiterated RatingOutperform ➝ Outperform$220.00
3/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$350.00
1/18/2024WedbushReiterated RatingOutperform ➝ Outperform$220.00
11/2/2023WedbushReiterated RatingOutperform$220.00
8/14/2023Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$240.00
8/11/2023Stifel NicolausLower Target$320.00 ➝ $300.00
8/11/2023WedbushLower TargetOutperform ➝ Outperform$360.00 ➝ $220.00
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$350.00
3/26/2023BarclaysLower Target$300.00 ➝ $200.00
3/24/2023OppenheimerReiterated RatingOutperform$360.00
3/24/2023Truist FinancialLower TargetBuy$340.00 ➝ $320.00
3/24/2023Stifel NicolausLower TargetBuy$340.00 ➝ $320.00
3/24/2023Robert W. BairdLower TargetOutperform$760.00 ➝ $440.00
3/24/2023HC WainwrightLower TargetBuy$400.00 ➝ $350.00
2/13/2023Citizens JmpReiterated RatingMarket Outperform$240.00
1/19/2023Citizens JmpLower TargetMarket Outperform$300.00 ➝ $240.00
11/14/2022OppenheimerLower TargetOutperform$540.00 ➝ $360.00
11/11/2022BarclaysLower TargetOverweight$520.00 ➝ $300.00
8/15/2022HC WainwrightLower TargetBuy$520.00 ➝ $400.00
7/26/2022WedbushReiterated RatingInitiates
7/25/2022WedbushInitiated CoverageOutperform$360.00
5/16/2022HC WainwrightReiterated RatingBuy$520.00
5/13/2022Citizens JmpLower Target$600.00 ➝ $300.00
4/27/2022The Goldman Sachs GroupInitiated CoverageNeutral$120.00
3/21/2022BarclaysLower TargetOverweight$1,120.00 ➝ $520.00
3/16/2022Citizens JmpLower TargetBuy$800.00 ➝ $600.00
3/15/2022HC WainwrightReiterated RatingBuy$520.00
1/24/2022B. Riley FinancialLower Target$1,200.00 ➝ $920.00
12/17/2021HC WainwrightInitiated CoverageBuy$520.00
12/2/2021Robert W. BairdInitiated CoverageOutperform$760.00
12/1/2021OppenheimerInitiated CoverageOutperform$600.00
10/19/2021Citizens JmpInitiated CoverageOutperform$800.00
5/7/2021B. Riley FinancialReiterated RatingBuy$1,200.00
(Data available from 5/3/2021 forward)

News Sentiment Rating

1.45 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 11 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 1 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2026
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2026
  • 24 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2026

Current Sentiment

  • 24 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Vor Biopharma logo
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $13.85
Low: $13.68
High: $14.32

50 Day Range

MA: $14.98
Low: $12.04
High: $18.05

52 Week Range

Now: $13.85
Low: $2.62
High: $65.80

Volume

543,979 shs

Average Volume

1,075,097 shs

Market Capitalization

$750.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.75

Frequently Asked Questions

What sell-side analysts currently cover shares of Vor Biopharma?

The following Wall Street analysts have issued reports on Vor Biopharma in the last year: Citigroup Inc., Citizens Jmp, HC Wainwright, Jefferies Financial Group Inc., JonesTrading, JPMorgan Chase & Co., Robert W. Baird, Stifel Nicolaus, TD Cowen, Wall Street Zen, Wedbush, Weiss Ratings, Wells Fargo & Company, and Zacks Research.
View the latest analyst ratings for VOR.

What is the current price target for Vor Biopharma?

0 Wall Street analysts have set twelve-month price targets for Vor Biopharma in the last year. Their average twelve-month price target is $50.56, suggesting a possible upside of 265.0%. Citizens Jmp has the highest price target set, predicting VOR will reach $120.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $15.00 for Vor Biopharma in the next year.
View the latest price targets for VOR.

What is the current consensus analyst rating for Vor Biopharma?

Vor Biopharma currently has 1 sell rating, 4 hold ratings, 6 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for VOR.

What other companies compete with Vor Biopharma?

Other companies that are similar to Vor Biopharma include Structure Therapeutics, Arcutis Biotherapeutics, Denali Therapeutics, Gemini Therapeutics and Dyne Therapeutics. Learn More about companies similar to Vor Biopharma.

How do I contact Vor Biopharma's investor relations team?

Vor Biopharma's physical mailing address is 100 CAMBRIDGEPARK DRIVE, SUITE 101, CAMBRIDGE, MA, 02140. The company's listed phone number is (617) 655-6580. The official website for Vor Biopharma is vorbio.com. Learn More about contacing Vor Biopharma investor relations.